Evolus, Inc. (EOLS) Stock Grade

About Evolus, Inc.'s fundamentals

Evolus is a specialty pharmaceutical company with a market capitalization of $524.2 million that is currently unprofitable, reporting a net loss and a negative net margin of -17.4% in its latest annual results. The company is experiencing revenue growth of 11.6% year-over-year, indicating expanding sales despite its current losses. Its unusually high return on equity of 223.5% reflects the company's negative equity base rather than strong profitability, which is a common characteristic of companies in turnaround or growth phases. The company does not pay a dividend and has no meaningful P/E ratio due to its loss-making status.